NTRK1 and prostate carcinoma: There are currently 14 ongoing or completed clinical trials using lestaurtinib for the treatment of various cancers including myelofibrosis, leukemia, prostate cancer, and neuroblastoma, and the TrkA pathway is a target for neuroblastoma therapy55.